The STELLAR trial will test the efficacy of oral eflornithine on recurring anaplastic astrocytoma. The trial is now open for patients to enrol.
Sponsored by Orbus Therapeutices, the trial is now open across North America, Europe and selected sites in the UK for eligible patients.
Anaplastic astrocytoma brain tumours are most common in adults aged 30 to 50 years, although it can affect all ages, if they recur after surgery, chemotherapy or radiotherapy there are currently few treatments available, something the STELLAR trial aims to investigate.
This phase 3 clinical trial will build on work that has shown that eflornithine may inhibit malignant tumour growth including intracerebral high-grade gliomas.
In 2014, eflornithine received breakthrough therapy designation from America’s FDA (The Food and Drug Administration) for the treatment of patients with anaplastic glioma.
In the trial, eflornithine will be administered orally, targeting a key enzyme called ornithine decarboxylase, that plays a part in cancer cell growth.
You may be eligible now if:
• Your doctor has told you that you have anaplastic astrocytoma
• You have already been treated with radiation and chemotherapy drug temozolomide
• Your doctor has told you that the tumour has come back or has grown or changed within the past three months
• You completed radiation therapy more than six months ago
• You are an adult over the age of 18 years